Theurillat Group

Theurillat Group

We aim to explore the role of SPOP and CHD1 mutations to develop new therapeutic avenues for prostate cancer.

Alimonti group

Alimonti group

Our research is focused on the characterization of a novel type of cellular senescence response for cancer therapy

Catapano group

Catapano group

We investigate strategies aimed at blocking selectively transcription of genes that might be implicated in pathogenesis of cancer

Bertoni group

Bertoni group

We apply genomics techniques followed by functional studies to elucidate the lesions underlying non-Hodgkin’s lymphomas

Fighting cancer through research. You can support us by making a donation, however large or small.

Support us

About

The lOR Institute of Oncology Research is part of the Research Division of the Oncology Institute of Southern Switzerland (IOSI), the comprehensive cancer center of the Ente Ospedaliero Cantonale (EOC), and is the main facility for basic and translational research at the IOSI. The Institute is directed by Carlo Catapano MD, PhD and comprises different groups working in the areas of tumor biology, cancer genomics, molecular oncology and experimental therapeutics. The expertise available in the Institute spans from cell and molecular biology to molecular pharmacology, genomics and bioinformatics. Th...

Read More

Director’s foreword

Mission statement

Cancer Research